Cellectar and NorthStar Partner to Advance Radiotherapy Development
Cellectar partners with NorthStar for Ac-225 supply, advancing CLR 121225 radiotherapy toward clinical trials.
Cellectar Biosciences has entered a 10-year agreement with NorthStar Medical Radioisotopes for a steady supply of non-carrier-added Actinium-225 (Ac-225), a rare and critical isotope for its CLR 121225 radiotherapeutic program. CLR 121225, which uses Cellectar’s Phospholipid Ether (PLE) delivery platform, has shown promise in preclinical studies targeting pancreatic and triple-negative breast cancers, among others.
This partnership addresses the limited global supply of Ac-225, enabling the progression of CLR 121225 to human clinical trials in 2025. The collaboration underlines a commitment to advancing alpha-emitting radiotherapies.
NorthStar’s expertise in producing high-purity Ac-225 ensures reliable support for Cellectar’s innovative therapeutic approach, which aims to bring first-in-class cancer treatments to market.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
Sanofi Appoints Archana Subramanya as Head of R&D India Hub
Kiora Pharmaceuticals Advances KIO-301 Phase 2 Enrollment Toward Coordinated Global Phase 3 Strategy
Discussion